SequelSEC

Moderna, Inc. MRNA

Biological Products, (No Diagnostic Substances) · CIK 0001682852 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.23B
Fiscal year ended 2026-06-30
Operating income
-$3.32B
Fiscal year ended 2026-06-30
Free cash flow
-$1.24B
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$9.90BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$25.07Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue5.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Long-term debt / equity0.07x15th
Revenue YoY growth-39.9%26th
CapEx / revenue9.9%72th
Current ratio3.29x37th
Operating margin-158.1%63th
FCF margin-106.2%61th
Gross margin55.3%39th
Net margin-145.2%61th
SBC / revenue24.8%40th
R&D / revenue161.1%44th

Moderna, Inc. (MRNA) reported revenue of $2.23B and net income of -$3.15B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Moderna, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Moderna, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$2.23B
Cost of revenue$1.71B
Gross profit$521.00M
Operating income-$3.32B
Net income-$3.15B
Research & development$2.88B
Weighted-average diluted sharesUnavailable
Pretax income-$3.09B
Income tax expense$64.00M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$965.00M
Selling & marketingUnavailable

Balance

Moderna, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.72B
Total assets$10.96B
Current assets$5.82B
Total liabilities$4.20B
Current liabilities$2.53B
Total equity incl. NCI$6.76B
Temporary (mezzanine) equityUnavailable
Inventory$280.00M
Accounts receivable$17.00M
Goodwill$52.00M
Long-term debt$591.00M
Accounts payable$167.00M

Cash flow

Moderna, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$1.07B
Capital expenditures$171.00M
Investing cash flow$905.00M
Financing cash flow$611.00M
Net change in cash$443.00M
Stock-based compensation$462.00M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$229.00M

Derived

Moderna, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$1.24B
Gross margin23.4%
Operating margin-149.0%
FCF margin-55.8%
SBC / revenue20.7%
Current ratio2.29x
Revenue YoY growth-27.6%
Net margin-141.4%
R&D / revenue129.1%
CapEx / revenue7.7%
Long-term debt / equity0.09x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MRNA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-01View SEC filing
10-K · Filed 2026-02-20View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-01View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.